164 related articles for article (PubMed ID: 21350089)
1. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.
Barakat FH; Medeiros LJ; Wei EX; Konoplev S; Lin P; Jorgensen JL
Am J Clin Pathol; 2011 Mar; 135(3):365-73. PubMed ID: 21350089
[TBL] [Abstract][Full Text] [Related]
2. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia.
Morice WG; Chen D; Kurtin PJ; Hanson CA; McPhail ED
Mod Pathol; 2009 Jun; 22(6):807-16. PubMed ID: 19287458
[TBL] [Abstract][Full Text] [Related]
3. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
4. Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.
Roberts MJ; Chadburn A; Ma S; Hyjek E; Peterson LC
Am J Clin Pathol; 2013 Feb; 139(2):210-9. PubMed ID: 23355206
[TBL] [Abstract][Full Text] [Related]
5. Persistent monotypic plasma cells with absence of neoplastic B cell component in a treated case of waldenström macroglobulinemia: a sign of residual disease?
Gajendra S; Sachdev R; Jha B; Goel S; Sahni T
J Clin Diagn Res; 2014 Nov; 8(11):FD12-3. PubMed ID: 25584235
[TBL] [Abstract][Full Text] [Related]
6. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
7. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells.
Remstein ED; Hanson CA; Kyle RA; Hodnefield JM; Kurtin PJ
Semin Oncol; 2003 Apr; 30(2):182-6. PubMed ID: 12720133
[TBL] [Abstract][Full Text] [Related]
8. The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.
Jalali S; Ansell SM
Hematol Oncol Clin North Am; 2018 Oct; 32(5):777-786. PubMed ID: 30190017
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic analysis of Waldenstrom's macroglobulinemia.
San Miguel JF; Vidriales MB; Ocio E; Mateo G; Sánchez-Guijo F; Sánchez ML; Escribano L; Bárez A; Moro MJ; Hernández J; Aguilera C; Cuello R; García-Frade J; López R; Portero J; Orfao A
Semin Oncol; 2003 Apr; 30(2):187-95. PubMed ID: 12720134
[TBL] [Abstract][Full Text] [Related]
10. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.
de Tute RM; Rawstron AC; Owen RG
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):211-3. PubMed ID: 23523273
[TBL] [Abstract][Full Text] [Related]
12. A Rare Case of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma with Light Chain Discrepancy between B Lymphocyte Population and Serum Paraprotein.
Kim HJ; Hur M; Kim H; Moon HW; Yun YM; Kim SY; Lee MH
Ann Clin Lab Sci; 2015; 45(5):593-7. PubMed ID: 26586715
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
14. Role of plasma cells in Waldenström macroglobulinaemia.
El-Ayoubi A; Wang JQ; Hein N; Talaulikar D
Pathology; 2017 Jun; 49(4):337-345. PubMed ID: 28483372
[TBL] [Abstract][Full Text] [Related]
15. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical phenotyping of plasma cells in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia is comparable to flow cytometric techniques.
Howard MT; Hodnefield J; Morice WG
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):96-8. PubMed ID: 21454202
[TBL] [Abstract][Full Text] [Related]
17. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
18. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
[TBL] [Abstract][Full Text] [Related]
19. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
Kapoor P; Paludo J; Ansell SM
Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
[TBL] [Abstract][Full Text] [Related]
20. [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Adam Z; Pour L; Krejčí M; Ševčíková S; Pourová E; Ševčíková E; Král Z; Mayer J
Vnitr Lek; 2016 Jan; 62(1):25-39. PubMed ID: 26967234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
